My name is Pyotr Garbuzov.
I represent the Tsyb Medical Radiology Research Centre, located in the city of Obninsk.
I'm a senior researcher in the department of brachytherapy.
Our department primarily treats patients with thyroid diseases, but in addition, many oncology patients receive our treatment, either for pain relief in the case of bone metastases, or as adjuvant therapy in the treatment of thyroid diseases.
My presentation at this symposium, at this forum, concerns specifically radiotherapy of thyroid cancer.
These are very important components for obtaining the maximum effect in patients who must be treated surgically, and the maximum effect can be achieved only when this combination is possible for the patients and they can get it in the optimal timeframe.
From my presentation, well, I essentially already tried to say what the implications could be.
Radiotherapy is not - it is widely used worldwide, but in Russia it's not always possible to have this procedure within the optimal timeframe.
In this situation, we have to be very careful when selecting the patients who need this treatment.
Current recommendations, which are updated annually, allow us to take a more careful approach to the group of patients who absolutely need this treatment.
These are the high-risk patients.
In this presentation, I want to point out that this treatment should be differentiated.
There are situations where surgery alone is sufficient, and you can get by without this procedure.
At the same time, there are patients with distant metastases who unquestionably require this procedure.
And we will primarily focus on that group of patients, so that this type of treatment can be performed in time.
What important points [inaudible]
This forum is a unique opportunity to interact with top world-class specialists,
The fact that the team with Jatin Shah is coming is a real bonus for specialists who work not only in the region of Russia, but also in the nearby areas that once made up the large country known as the Soviet Union.
This opportunity is made possible by the organizers of this event, who ensured that the English language would be accessible through an interpreter.
But now, more and more, it happens that we understand each other when we are discussing an issue, without the limitations of a language barrier.
And the way things are going with this interaction is also very good in that the interaction outside of the conference also enables us to expand our professional networks and discuss the issues that come up in the presentations in greater depth and detail, in order to better understand each other.
The issue of radionuclide therapy does not have a very long history, just half a century.
And today there are great expectations that the development of this issue and this technology will be increasingly rapid.
In this case, our new knowledge that we have today will be promising so that patients who need this technology could receive this treatment.
